Previous 10 | Next 10 |
Zai Lab Limited (ZLAB) Q2 2020 Earnings Conference Call August 13, 2020 8:00 AM ET Company Participants Billy Cho – Chief Financial Officer Samantha Du – Founder, Chair Person and Chief Executive Officer Tao Fu – President and Chief Operating Officer Jonath...
The following slide deck was published by Zai Lab Limited in conjunction with their 2020 Q2 earnings Read more ...
-- Company to Host Conference Call and Webcast Today at 8:00 a.m. EDT -- -- Recent highlights include successful ZEJULA and Optune commercial launches, NMPA approval for Optune, two highly strategic collaboration deals and three NDAs accepted with priority review -- SHANGHAI and SAN FR...
COVID-19 Pandemic BioKangtai (SHZ: 300601), a Guangdong vaccine company, in-licensed rights to develop, manufacture and market AstraZeneca's (AZN) COVID-19 vaccine in China. The candidate is an adenovirus vector-based COVID-19 vaccine that was created by Oxford University and partnered b...
SHANGHAI and SAN FRANCISCO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced that the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) has granted priority ...
-- Company to host Conference Call and Webcast on August 13, 2020 at 8:00 a.m. ET -- SHANGHAI and SAN FRANCISCO, July 30, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced it will report financial results f...
China NMPA acceptance of NDA follows recent U.S. FDA approval for the treatment of adult patients with advanced GIST who have received prior treatment with 3 or more kinase inhibitors, including imatinib SHANGHAI, China and SAN FRANCISCO and WALTHAM, Mass., July 20, 2020 (GLOBE NEWSWI...
Deals and Financings Ocumension [HK:1477], a Shanghai ophthalmic pharma, completed a $184 million Hong Kong IPO and climbed 152% in its first trading session, giving the company a valuation of about $2.5 billion (see story ). Founded in 2017, Ocumension was incubated by 6 Dimensions Capital...
Turning Point Therapeutics (NASDAQ: TPTX) on Tuesday licensed Greater China rights to its tyrosine kinase inhibitor, repotrectinib, to Zai Lab (NASDAQ: ZLAB) for $25 million in cash up front, plus up to $151 million in development, regulatory and sales milestones, and tiered mid-to...
Turning Point Therapeutics ( TPTX +0.6% ) signs an agreement with Zai Lab ( ZLAB +4.3% ) for Turning Point’s lead drug candidate, repotrectinib for lung cancer. More news on: Turning Point Therapeutics, Inc., Zai Lab Limited, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study Zai Lab Limited (NASDAQ: Z...
Manuscript represents the first publication from China’s gynecology oncology field to be published in Cell Publication highlights first-time learnings about the landscape of ovarian cancer microenvironment stratified by HRD and how a PARP inhibitor perturbs it Data suggest ...
2024-07-05 18:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...